Dallas Renal Group

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• IgA nephropathy6 trials
• Chronic kidney disease3 trials
• High blood pressure1 trial
• Lupus (SLE)1 trial

Phase

• Phase 36 trials
• Phase 11 trial
• Phase 21 trial
• Phase 41 trial

Status

• Recruiting4 trials
• Active, not recruiting3 trials
• Completed3 trials

Lead sponsor

• Novartis Pharmaceuticals3 trials
• Alpine Immune Sciences Inc, A Subsidiary of Vertex1 trial
• Asahi Kasei Therapeutics, AB1 trial
• Biocon Limited1 trial
• E-Star BioTech, LLC1 trial
• and 3 more

Running trials

• Recruiting

  Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

  NCT06858319· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Phuong Truong (principal investigator)

• Recruiting

  A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

  NCT06963827· Phase 3· Takeda· Source

  Contact: Irfan Agha (principal investigator)

• Active, not recruiting

  Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy

  NCT06712407· Phase 4· Asahi Kasei Therapeutics, AB· Source

• Recruiting

  To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension

  NCT06343298· Phase 2· E-Star BioTech, LLC· Source

  Contact: BOLD-HTN

• Recruiting

  Behavioral AI to Predict and Increase Peritoneal Dialysis Uptake

  NCT06533254· Scaled Insights· Source

  Contact: Veronica Almanza

• Active, not recruiting

  Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06564142· Phase 3· Alpine Immune Sciences Inc, A Subsidiary of Vertex· Source

• Recruiting

  A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

  NCT04557462· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• IgA nephropathy2 recruiting
• Chronic kidney disease1 recruiting
• High blood pressure1 recruiting

Closed trials

• Completed

  Vafseo Outcomes In-Center Experience

  NCT06520826· Phase 3· USRC Kidney Research· Source

• Completed

  Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

  NCT04578834· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis

  NCT04128579· Phase 1· Biocon Limited· Source